Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up
by Kaibalya Pravo Dey
While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.
Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.
Biotech Sector in Focus as Coronavirus Spreads Panic
by Ekta Bagri
The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.
The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway
Top Analyst Reports for Amazon, IBM & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), International Business Machines Corporation (IBM) and Biogen Inc. (BIIB).
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
by Zacks Equity Research
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.
Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies
by Zacks Equity Research
Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies
Stocks the Pros Loved Heading into 2020
by Tracey Ryniec
As stocks hit new all-time highs to finish 2019, the professional money managers were busy positioning their portfolios for 2020. What were they buying, and selling, heading into the new year?
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen
Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas
by Sanghamitra Saha
Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Lilly Reports Disappointing Data on Alzheimer's Candidate
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.
Roche Reports Disappointing Data on Alzheimer's Disease Drug
by Zacks Equity Research
Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
Top Stock Research Reports for Alphabet, Roche & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Roche Holding (RHHBY) and Amgen (AMGN).
Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan
by Zacks Equity Research
The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod
by Zacks Equity Research
Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.
Biogen (BIIB) Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter.